With $172 Million Raise, Wugen Brings Natural Killer Therapies to Solid Tumors Next
Published: Jul 15, 2021 By Kate Goodwin The NK program has taken off with multiple indications. According to Dan Kemp, its lead product, WU-NK-101, is already proving itself in an ongoing Phase I/II trial, demonstrating an "impressive complete response rate in relapsed/refractory AML." It's the promising results of these memory NK cells driving Company founder John McKearn told BioSpace in January that Wugen "started as a twinkle in his eye" to bring a durable, allogeneic CAR-T therapy on the market. At that time, the biotech's natural killer (NK) cell program was a recent additi...
Source: biospace.com